OpenAI is considering a radical business model shift, where it would take a percentage of revenue from commercial outcomes customers achieve using its AI. This includes drug discovery, new materials, or chip designs accelerated by its models. The plan is still internal but targets high-value R&D sectors like pharma and tech.

This moves beyond traditional API billing, tying OpenAI's success directly to customer innovation. It mirrors cloud or EDA industry models but applies them to large language models. Supporters see it aligning incentives for basic research investment, while critics warn of complex IP disputes and legal hurdles for businesses.

OpenAI hasn't disclosed specific terms, but the move aims to capture more value from its $20B+ annual revenue. It could reshape AI competition into a battle for ecosystem influence. Watch for how this affects enterprise adoption and whether rivals like Google or Anthropic follow suit with similar value-sharing frameworks.